Category: Prostate Cancer

Author Published on

In mouse models immune cell manipulation plus chemotherapy achieves prostate cancer remission where chemotherapy alone fails

Blocking or removing immune-suppressing cells , researchers at the University of California, San Diego School of Medicine have found, allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors.

This combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. ...continue reading Targeting B Cells to Tackle Immune System Suppression in High Risk Prostate Cancers

Author Published on

Advocating for advanced prostate cancer patients in Scotland, Alister Walker, Chairman and volunteer in Perth & Kinross Prostate Cancer Support Group, writes in the Scottish newspaper The Herald:

"Last week we read the good news that Moderator-Designate of the General Assembly of the Church of Scotland, the Reverend Dr Angus Morrison, has overcome the disease (Church leader in cancer warning , The Herald, April 23). With prostate cancer so often being symptomless in its early stages he is right to urge other men to consider speaking to their GP about the disease. This is particularly important for men aged over 50, black men and men whose father or brother has had the disease - who are at a higher risk. ...continue reading Abiraterone rejection in Scotland must be overturned, Prostate Cancer advocate says

Author Published on

Dr Leszek Kotula, co-author of the WAVE1 study, explains in this video from 2013  how basic science research in his lab at Upstate Medical University in Syracuse, NY will benefit prostate cancer patients with better diagnostic and treatment options.

April 7, 2015. Researchers at Upstate Medical University, NY and Harvard University have linked the loss of key gene, WAVE1, to a lethal form of prostate cancer. They found that  in patients who were treated for prostate cancer, alterations in the WAVE1 gene were associated with a shorter remission.

...continue reading Loss of WAVE1 gene linked to lethal prostate cancer

Author Published on

April 23, 2015. African American men have the highest rates of prostate cancer incidence and mortality in the United States. For the past twenty years cancer researchers have worried about this and researched various causal factors. Now a large study suggests obesity may play an important role in what specialists in disparities in prostate cancer risk are calling the "African-American race effect.

...continue reading Obesity Significantly Increases Prostate Cancer Risk in African-American Men

Author Published on

A device to lower side effects of radiation treatment for prostate cancer, newly approved in the USA, has been used this month on the first patient. The device injects a temporary gel to create a space between the prostate and the rectum.

Named the SpaceOAR System (“OAR” stands for “organ at risk”), the system received FDA clearance on April 1. FDA granted clearance after a US clinical trial showing that SpaceOAR hydrogel achieved a significant reduction in rectal radiation dose and late rectal toxicity.
...continue reading Injectable Gel Improves Radiation for Prostate Cancer

Author Published on

The PSA test is the first step in the early detection of prostate cancer.

As such it must be used as part of a skilled diagnostic process and selective treatment process. When to start and stop screening, at what intervals to conduct screening, and when to biopsy are among questions we look at here.

...continue reading PSA Test – do you need it?

Author Published on

(TORONTO, Canada – Jan. 24, 2012) – For men diagnosed with low-risk, localized prostate cancer, treatment with dutasteride (brand name “Avodart”) delays disease progression, a 3-year study has found. The drug is classed as a 5a-reductase inhibitor. In men opting at this stage for "Active Surveillance," Avodart delayed the start of more active treatment while reducing anxiety.

...continue reading Avodart Delays Low-Risk Prostate Cancer Progression, Study Finds

Author Published on

Active surveillance may be a viable option for some men with prostate cancer. Regular tests and careful tracking of any changes in the patient's disease risk over time are imperative to ensure good outcomes, according to researchers in Toronto presenting at the annual meeting of the American Urological Association (AUA).

Active surveillance is typically offered to men with prostate cancer if biopsy results, staging and PSA doubling time all indicate that the tumor is so small and slow-growing that it is unlikely to develop into fatal illness within the man's lifetime.

...continue reading For Low Risk Prostate Cancer, Personalized Monitoring An Option